Key result
Extended pulse cyclophosphamide outperforms 6-month methylprednisolone for preserving renal function in severe lupus nephritis.
Answers are grounded in this paper and cite their sources.
PURPOSE: To review advances and controversies in the diagnosis and management of systemic lupus erythematosus with visceral involvement (renal, neuropsychiatric, cardiopulmonary, and hematologic disease). DATA SOURCES AND STUDY SELECTION: Review of the English-language medical literature with emphasis on articles published in the last 5 years. More than 400 articles were reviewed. DATA SYNTHESIS: Recent debates pertaining to lupus nephritis have focused on the value of kidney biopsy data and the role of cytotoxic drug therapies. Many studies have shown that estimates of prognosis are enhanced by consideration of clinical, demographic, and histologic features. For patients with severe lupus nephritis, an extended course of pulse cyclophosphamide therapy is more effective than a 6-month course of pulse methylprednisolone therapy in preserving renal function. Adding a quarterly maintenance regimen to monthly pulse cyclophosphamide therapy reduces the rate of exacerbations. Plasmapheresis appears not to enhance the effectiveness of prednisone and daily oral cyclophosphamide. Small case series have shown pulses of cyclophosphamide to be beneficial in patients with lupus and neuropsychiatric disease refractory to glucocorticoid therapy, acute pulmonary disease (pneumonitis or hemorrhage), and thrombocytopenia. Patients with systemic lupus erythematosus have an increased prevalence of valvular and atherosclerotic heart disease, apparently because of factors related to the disease itself and to drug therapy. CONCLUSIONS: Cytotoxic agents are superior to glucocorticoid therapy for the treatment of proliferative lupus nephritis, but the optimal duration and intensity of cytotoxic therapy remain undefined. Definitive studies of the treatment of autoimmune thrombocytopenia and acute pulmonary disease and of the diagnosis and treatment of neuropsychiatric disease are not available.
No takes yet. Share an insight, caveat, or question.
Dimitrios T. Boumpas (1995) conducted a review in Systemic lupus erythematosus with visceral involvement (renal, neuropsychiatric, cardiopulmonary, and hematologic disease). Cytotoxic drug therapies (e.g., pulse cyclophosphamide) vs. Glucocorticoid therapy (e.g., pulse methylprednisolone, prednisone) was evaluated on Preservation of renal function and rate of exacerbations in severe/proliferative lupus nephritis. Extended pulse cyclophosphamide is superior to 6-month pulse methylprednisolone for preserving renal function in severe lupus nephritis across >400 reviewed articles.
Synapse has enriched 10 related papers. Consider them for comparative context: